Cargando…

Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status

Tremelimumab, an anti‐cytotoxic T‐lymphocyte antigen‐4 monoclonal antibody that enhances T‐cell activation, was evaluated in a randomized, double‐blind, placebo‐controlled, phase IIb study (NCT01843374) in patients with unresectable malignant mesothelioma. The study demonstrated no clinically meanin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baverel, Paul, Roskos, Lorin, Tatipalli, Manasa, Lee, Nancy, Stockman, Paul, Taboada, Maria, Vicini, Paolo, Horgan, Kevin, Narwal, Rajesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742946/ https://www.ncbi.nlm.nih.gov/pubmed/30883000 http://dx.doi.org/10.1111/cts.12633

Ejemplares similares

A phase 2 randomized, double-blind, placebo-controlled study of tremelimumab for second and third line treatment in patients with unresectable pleural or peritoneal mesothelioma
por: Krug, Lee, et al.
Publicado: (2013)

Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma
por: Zheng, Yanan, et al.
Publicado: (2018)

Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2022)

A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition
por: Gong, Chang, et al.
Publicado: (2017)

Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status
por: Baverel, Paul G., et al.
Publicado: (2018)

Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus
por: Narwal, Rajesh, et al.
Publicado: (2013)

Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma
por: Ahmed, Zunirah, et al.
Publicado: (2023)

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
por: Song, Xuyang, et al.
Publicado: (2023)

Tremelimumab
Publicado: (2012)

A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer
por: Jafarnejad, Mohammad, et al.
Publicado: (2019)

A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade
por: Milberg, Oleg, et al.
Publicado: (2019)

Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma
por: Porta, Camillo, et al.
Publicado: (2008)

In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model
por: Wang, Hanwen, et al.
Publicado: (2019)

Computed Tomography and Spirometry Can Predict Unresectability in Malignant Pleural Mesothelioma
por: Bellini, Alice, et al.
Publicado: (2021)

Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma
por: Arends, Rosalinda, et al.
Publicado: (2021)

Tremelimumab: research and clinical development
por: Comin-Anduix, Begoña, et al.
Publicado: (2016)

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
por: Hotta, Katsuyuki, et al.
Publicado: (2020)

Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival
por: Quetel, Lisa, et al.
Publicado: (2020)

Survivin expression as an independent predictor of overall survival in malignant peritoneal mesothelioma
por: Zhang, Guozun, et al.
Publicado: (2020)

Prognostic factors for progression‐free and overall survival in malignant pleural mesothelioma
por: Guzmán‐Casta, Jordi, et al.
Publicado: (2021)

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
por: Kelley, Robin Kate, et al.
Publicado: (2021)

Model‐Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab
por: Wang, Bing, et al.
Publicado: (2017)

Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis
por: Wang, Bi-Cheng, et al.
Publicado: (2020)

SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma
por: Zhang, Yi, et al.
Publicado: (2013)

DNA Methylation of FKBP5 as Predictor of Overall Survival in Malignant Pleural Mesothelioma
por: Cugliari, Giovanni, et al.
Publicado: (2020)

Remission of an Intracardiac Melanoma Metastasis after Tremelimumab Therapy
por: Spethmann, Sebastian, et al.
Publicado: (2014)

An Uncommon Case of Myocarditis Secondary to Durvalumab Plus Tremelimumab
por: Diaz-Rodriguez, Porfirio E, et al.
Publicado: (2023)

Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data
por: Kutuk, Tugce, et al.
Publicado: (2022)

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
por: Ye, Zhuo-miao, et al.
Publicado: (2022)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Multimodality treatment of malignant pleural mesothelioma
por: Berzenji, Lawek, et al.
Publicado: (2018)

Malignant mesothelioma
por: Ruffié, P, et al.
Publicado: (2001)

Malignant mesothelioma
por: Moore, Alastair J, et al.
Publicado: (2008)

Malignant mesothelioma
por: Ahmed, Ishtiaq, et al.
Publicado: (2013)

Malignant Mesothelioma
por: Pouliquen, Daniel L., et al.
Publicado: (2021)

Predicting Overall Survival for Patients with Malignant Mesothelioma Following Radiotherapy via Interpretable Machine Learning
por: Wang, Zitian, et al.
Publicado: (2023)

Editorial: Emerging Therapies for Malignant Mesothelioma
por: van Zandwijk, Nico, et al.
Publicado: (2020)

Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab
por: Ibarrondo, F. Javier, et al.
Publicado: (2013)

Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
por: Arru, Caterina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9dkc3ikaj2o3q2sadj2u36bk24